CSL share price 'will be significantly bigger from this point': fundie

This fund manager has tipped growth of 10% to 30% for some ASX share opportunities like CSL.

| More on:
A woman in workout gear flexes her muscles while holding a juice.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The market has sold off a number of businesses that are viewed as high quality
  • Businesses such as CSL are opportunities, according to Ben Clark from TMS Capital
  • CSL is expected to make between US$2.15 billion and US$2.25 billion of net profit in FY22

The CSL Limited (ASX: CSL) share price has fallen around 20% since the recent high in November 2021. One fund manager thinks that the healthcare business is an opportunity.

CSL is one of the biggest healthcare businesses in Australia, specialising in developing biotherapies and influenza vaccines.

Ben Clark from TMS Capital was talking with Livewire about the market volatility we've seen recently.

Clark suggests it's a good time to be looking at higher-quality names that have been sold off.

Businesses with "pricing power, strong balance sheets and can grow despite what the economy will do" are the ones to focus on. Clark said to Livewire:

A lot of high-quality growth stocks are down at least 50% since 1 January. They're, arguably, where you want to be in this uncertain environment, in companies that can grow between 10% and 30% regardless of what the economy does.

Focus on the long term

Clark has a portfolio of names, including CSL, that are viewed as high quality. They include ResMed (ASX: RMD), REA Group Limited (ASX: REA), SEEK Limited (ASX: SEK), Macquarie Group Ltd (ASX: MQG), and Wesfarmers Ltd (ASX: WES).

His advice for nervous investors is to invest for the longer term and not worry about what's happening each week with the ASX share market.

If you're in high-quality growth businesses, you can take a long-term view. If you're in speculative stocks you do need to be worried, because there are a lot of businesses that might never come back.

But try not to react on a day-to-day basis, think truly five years ahead and stick to your plan.

Lower share prices hurt… but they could be opportunities

Understandably, some investors are finding this period a bit stressful. But for Clark, owning businesses like CSL makes it a bit easier to get through this period.

In his opinion, the CSL share price (and others) could recover nicely and grow from here.

Clark said, according to Livewire:

I'm not losing any sleep owning those businesses through this cycle – it's not fun seeing the share prices lower than where they should be, but those companies will be significantly bigger from this point.

CSL expectations

While the company can't make any commitments regarding the CSL share price, it has provided guidance about its expected FY22 net profit after tax (NPAT). The guidance is for NPAT of between US$2.15 billion to US$2.25 billion at constant currency. That includes $90 million to $110 million in transaction costs related to the agreement to acquire Vifor Pharma.

In mid-February, the ASX healthcare share noted that following initiatives it had implemented in its plasma collections network, collections had been improving and were expected to underpin "stronger sales" in its core plasma therapies. Strong influenza vaccine demand was helping Seqirus (which comes under the CSL group).

The acquisition of Vifor Pharma has been delayed. Vifor Pharma is a global specialty pharmaceutical company with "leadership in renal disease and iron deficiency".

CSL share price valuation

According to CommSec, the CSL share price is valued at 36x FY22's estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. and Wesfarmers Limited. The Motley Fool Australia has recommended Macquarie Group Limited, REA Group Limited, and SEEK Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »